Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy

NCT04562922 is registered in ClinicalTrials.gov with VitalMel as lead sponsor.

NCT NCT04562922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
Lead sponsor
VitalMel
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2013
Completion date
April 4, 2016
Enrollment
39 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adverse event, neutropenia